You are browsing the Hong Kong website, Regulated by Hong Kong SFC (CE number: BJA907). Investment is risky and you must be cautious when entering the market.
《大行報告》野村:美參議院法案消息或令內地CRO板塊的投資者情緒惡化
野村發表報告指,美國參議院通過《生物安全法案》,該決定或令內地全球生技製藥產生委外代工(CRO)板塊的投資者情緒惡化,從而影響內地CRO,主因美國是他們的重要市場。該行舉例指,截至2023年上半年,藥明生物(02269.HK)、藥明康德(02359.HK)、康龍化成(03759 HK),昭衍新藥(06127.HK)的總銷售額分別有46%、66%、65% 和29%來自美國地區或美國客戶,而泰格醫藥(03347.HK)和凱萊英(06821.HK)分別有44%和84%的銷售額來自其海外業務(其中絕大多數來自美國)。 該行預料,相關CRO板塊股價或因而受到負面影響,加上在今年美國總統大選下,即使該法案已通過,但需時進行立法以及修改法案等工作,地緣政治因素仍是懸而未決的問題,故該行建議要密切留意其發展方向。(ca/k) ~
Follow us
Find us on Facebook, Twitter , Instagram, and YouTube or frequent updates on all things investing.Have a financial topic you would like to discuss? Head over to the uSMART Community to share your thoughts and insights about the market! Click the picture below to download and explore uSMART app!
Disclaimers
uSmart Securities Limited (“uSmart”) is based on its internal research and public third party information in preparation of this article. Although uSmart uses its best endeavours to ensure the content of this article is accurate, uSmart does not guarantee the accuracy, timeliness or completeness of the information of this article and is not responsible for any views/opinions/comments in this article. Opinions, forecasts and estimations reflect uSmart’s assessment as of the date of this article and are subject to change. uSmart has no obligation to notify you or anyone of any such changes. You must make independent analysis and judgment on any matters involved in this article. uSmart and any directors, officers, employees or agents of uSmart will not be liable for any loss or damage suffered by any person in reliance on any representation or omission in the content of this article. The content of the article is for reference only and does not constitute any offer, solicitation, recommendation, opinion or guarantee of any securities, virtual assets, financial products or instruments. Regulatory authorities may restrict the trading of virtual asset-related ETFs to only investors who meet specified requirements. Any calculations or images in the article are for illustrative purposes only.
Investment involves risks and the value and income from securities may rise or fall. Past performance is not indicative of future performance. Please carefully consider your personal risk tolerance, and consult independent professional advice if necessary.
uSMART
Wealth Growth Made Easy
Open Account